First 100 Patients in the U.S. Treated with OssDsign Catalyst

OssDsign announced that the first 100 patients in the U.S. have now been treated with the company’s synthetic bone graft OssDsign Catalyst. The product was launched in the U.S. market in 2021, and has since then been adopted by surgeons for use in spinal fusion surgeries.

OssDsign Catalyst synthetic bone graft stimulates the formation of...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us